The Analyst Verdict: Johnson & Johnson In The Eyes Of 12 Experts
Portfolio Pulse from Benzinga Insights
Johnson & Johnson (NYSE:JNJ) has been evaluated by 12 analysts over the last three months, with a mix of bullish and indifferent sentiments. The average 12-month price target is $191.83, up from the previous $172.50. Analysts from firms like Morgan Stanley, Cantor Fitzgerald, RBC Capital, Raymond James, Wells Fargo, and UBS have provided various ratings and price target adjustments. Johnson & Johnson is a large healthcare firm with pharmaceutical, medical devices, diagnostics, and consumer divisions, with the consumer group set to be divested in 2023. The company has shown strong financial performance with a high net margin of 121.91% and ROE of 35.56%, but its revenue growth rate of 6.78% is below the Health Care sector average.
January 24, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson has received diverse analyst ratings with an updated average 12-month price target of $191.83. The company's strong financials may support positive investor sentiment, despite revenue growth lagging behind the sector average.
The updated average price target suggests analysts see potential for stock appreciation, which could lead to a positive short-term impact on JNJ's stock price. The strong financial metrics such as net margin and ROE reinforce this outlook, although the below-average revenue growth could temper some of the enthusiasm. The high relevance score is due to the direct focus on JNJ in the article, and the importance score reflects the significance of analyst ratings and financial performance on stock prices. The confidence level is high due to the clear consensus among analysts and the detailed financial data provided.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100